Acute tumor lysis syndrome in solid tumors—a case report and review of the literature L. BaeksgaardJ. B. Sørensen Review 28 February 2003 Pages: 187 - 192
Toxicity of a quinocarmycin analog, DX-52-1, in rats and dogs in relation to clinical outcome Jon C. MirsalisJanice Schindler-HorvatSusan J. Donohue Original Article 18 January 2003 Pages: 193 - 201
Ritterazine B, a new cytotoxic natural compound, induces apoptosis in cancer cells Takefumi KomiyaNobuhiro FusetaniKazuhiko Nakagawa Original Article 14 January 2003 Pages: 202 - 208
Growth suppression of a tumorigenic rat liver cell line by the anticancer agent, ET-18-O-CH3, is mediated by inhibition of cytokinesis Hye-Kyung NaChia-Cheng ChangJames E. Trosko Original Article 28 February 2003 Pages: 209 - 215
Stimulation of intestinal epithelial restitution by prostaglandin E1 analogue Kohji HirataToshiharu Horie Original Article 26 February 2003 Pages: 216 - 220
Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies Bea PauwelsAnnelies E. C. KorstJan B. Vermorken Original Article 22 January 2003 Pages: 221 - 226
Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors Nithya RamnathGary N. SchwartzPatrick J. Creaven Original Article 25 February 2003 Pages: 227 - 230
Phase I trial of continuous infusion 5-aza-2′-deoxycytidine A. AparicioC. A. EadsJ. S. Weber Original Article 27 February 2003 Pages: 231 - 239
Intermittent FLDP: 24-h infusion of 5-FU on days 1, 3 and 5 combined with low-dose cisplatin on days 1–5 for gastric cancer, and its pharmacologic and kinetic rationale Masanori TerashimaTakashi IrinodaTetsuhiko Shirasaka Original Article 11 February 2003 Pages: 240 - 246
Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts Ningping FengHongnan JinAiping H. Young Original Article 05 March 2003 Pages: 247 - 255
Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia Akitoshi KinoshitaYoshihiro KurosawaShinpei Nakazawa Original Article 17 January 2003 Pages: 256 - 260
Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT Sebastian BauerChristopher L. CorlessJochen Schütte Clinical Trial Report 26 February 2003 Pages: 261 - 265
Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment Alexander KianiClaus-Henning KöhneEberhard Schleyer Clinical Trial Report 04 March 2003 Pages: 266 - 270